When was Histogenics founded?

Histogenics was founded in 2000 and raised its 1st funding round 6 years after it was founded.

Where is Histogenics located?

Histogenics is headquartered in Waltham, United States. It is registered at Malvern, Pennsylvania.

How many employees does Histogenics have?

As of Sep 30, 2026, the latest employee count at Histogenics is 10.

Is Histogenics a funded company?

Histogenics is a funded company, having raised a total of $116M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 22, 2006.

When was the latest funding round of Histogenics?

Histogenics' latest funding was a $***** Post IPO round on Sep 16, 2016, with participation from 0 investor.

Where does Histogenics rank among its competitors?

Histogenics ranks 47th amongst 216 active competitors, of which 56 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Pandorum, which secured $429K in Mar, 2026.

Who are the top competitors of Histogenics?

Histogenics' top competitors include argenx, Tenaya Therapeutics and Vor Biopharma. Among them, Pandorum secured the most recent funding round in March, 2026.

Histogenics - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of restorative cell therapies for orthopedic diseases. The company's flagship product, NeoCart is a proprietary RCT that rebuilds a patient’s own knee cartilage, treating pain at the source and potentially preventing progression to osteoarthritis (OA).

Website: histogenics.com
Registered Address: Malvern, Pennsylvania

Key Metrics

Founded Year

2000

Location

Waltham, United States

Stage

Public

Total Funding

$116M in 6 rounds

Latest Funding Round

Post IPO, Sep 16, 2016, $*****

Investors

Sofinnova Investments & 7 more

Ranked

47^th among 216 active competitors

Employee Count

10 as on Sep 30, 2026

Investment & Acquisitions

ProChon Biotech

Similar Companies

argenx & 259 more

Exit Details

Public

View Histogenics' full profile

Histogenics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ocugen, Inc. CIN: 463679209 , United States, Active	Dec 26, 999	-	69 (As on Dec 31, 2024)	-

Histogenics got listed on Dec 02, 2014.

Click here to take a look at Histogenics's IPO in detail

Histogenics has raised a total funding of $116M over 6 rounds. Its first funding round was on Aug 22, 2006. Histogenics has 8 institutional investors.

Here is the list of recent funding rounds of Histogenics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 16, 2016	8383564	Post IPO	4329898	4941645	2117257	5931160
Jan 06, 2014	4838384	Series C	4862286	5534717	4778537	2224145
Jul 24, 2012	7161459	Series C	5636683	6645828	Sofinnova Investments	Split Rock Partners & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Histogenics's funding rounds and investors

Histogenics' employee count trend

Histogenics has 10 employees as of Sep 26. Here is Histogenics's employee count trend over the years:

Uncover Histogenics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Histogenics include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Histogenics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
3rd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
4th	Pandorum 2011, Bengaluru (India), Series B	Developer of regenerative medicine and 3D tissues	$52.1M	Indian Angel Network, BTB Venture & 89 others	65/100
5th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	63/100
6th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
7th	Tune Therapeutics 2009, Seattle (United States), Series B	Developer of cell and gene therapy by using the epigenomic platform	$222M	New Enterprise Associates, Emerson Collective ... & 9 others	63/100
8th	LIfT Biosciences 2016, London (United Kingdom), Series A	Developer of neutrophil-based cell therapies for solid tumors	$20.1M	Downing, Kizoo & 13 others	61/100
9th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Atlas Venture, Avoro Capital & 4 others	61/100
10th	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	Dolby Family Ventures, Alzheimer's Drug Discovery ... & 22 others	61/100
47th	Histogenics 2000, Waltham (United States), Public	Developer of restorative cell therapies for orthopedic diseases	$116M	Inflection Point Ventures, Split Rock Partners ... & 6 others	40/100